TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.21 CNY | -1.33% |
|
-0.49% | -1.24% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 10,158 | 11,542 | 13,690 | 16,133 | 12,061 | 11,924 |
| Enterprise Value (EV) 1 | 9,323 | 10,460 | 13,068 | 15,627 | 11,556 | 11,093 |
| P/E ratio | 31.9 x | 31.6 x | 33.8 x | 22.6 x | 25.7 x | 20.5 x |
| Yield | 1.63% | 1.61% | 1.31% | 1.93% | 1.71% | 2.13% |
| Capitalization / Revenue | 8.37 x | 8.23 x | 9.27 x | 9.11 x | 5.9 x | 5.83 x |
| EV / Revenue | 7.68 x | 7.46 x | 8.85 x | 8.83 x | 5.65 x | 5.42 x |
| EV / EBITDA | 28.5 x | 29.6 x | 32.9 x | 32.8 x | 19.2 x | 20.2 x |
| EV / FCF | 35.8 x | 43.3 x | -36.4 x | 27 x | -21,531 x | 24.2 x |
| FCF Yield | 2.79% | 2.31% | -2.75% | 3.7% | -0% | 4.13% |
| Price to Book | 5.01 x | 5.12 x | 5.23 x | 5.1 x | 3.63 x | 3.21 x |
| Nbr of stocks (in thousands) | 527,124 | 530,181 | 527,964 | 527,916 | 527,842 | 530,193 |
| Reference price 2 | 19.27 | 21.77 | 25.93 | 30.56 | 22.85 | 22.49 |
| Announcement Date | 4/18/19 | 4/28/20 | 4/15/21 | 4/28/22 | 4/27/23 | 4/18/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,213 | 1,403 | 1,476 | 1,770 | 2,045 | 2,045 |
| EBITDA 1 | 327.6 | 353.8 | 397 | 476 | 603.1 | 550.1 |
| EBIT 1 | 305.3 | 318.6 | 354.1 | 416.4 | 527.7 | 467.5 |
| Operating Margin | 25.16% | 22.71% | 23.99% | 23.52% | 25.81% | 22.86% |
| Earnings before Tax (EBT) 1 | 350.3 | 401.3 | 446.7 | 787.9 | 519.2 | 644.4 |
| Net income 1 | 318.8 | 364.3 | 405.7 | 715.9 | 472.4 | 581.2 |
| Net margin | 26.27% | 25.97% | 27.48% | 40.43% | 23.1% | 28.42% |
| EPS 2 | 0.6047 | 0.6900 | 0.7675 | 1.353 | 0.8907 | 1.096 |
| Free Cash Flow 1 | 260.5 | 241.6 | -359.5 | 577.8 | -0.5367 | 457.6 |
| FCF margin | 21.47% | 17.23% | -24.35% | 32.63% | -0.03% | 22.38% |
| FCF Conversion (EBITDA) | 79.53% | 68.3% | - | 121.38% | - | 83.19% |
| FCF Conversion (Net income) | 81.73% | 66.33% | - | 80.71% | - | 78.74% |
| Dividend per Share 2 | 0.3140 | 0.3500 | 0.3400 | 0.5900 | 0.3900 | 0.4800 |
| Announcement Date | 4/18/19 | 4/28/20 | 4/15/21 | 4/28/22 | 4/27/23 | 4/18/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 836 | 1,082 | 622 | 506 | 505 | 831 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 261 | 242 | -359 | 578 | -0.54 | 458 |
| ROE (net income / shareholders' equity) | 16.1% | 16.9% | 16.6% | 24.3% | 14.2% | 16.2% |
| ROA (Net income/ Total Assets) | 8.28% | 7.52% | 5.95% | 5.19% | 5.76% | 4.8% |
| Assets 1 | 3,850 | 4,845 | 6,822 | 13,794 | 8,203 | 12,120 |
| Book Value Per Share 2 | 3.850 | 4.250 | 4.960 | 5.990 | 6.300 | 7.020 |
| Cash Flow per Share 2 | 0.7500 | 2.560 | 3.470 | 1.260 | 0.8300 | 0.7600 |
| Capex 1 | 129 | 52.3 | 339 | 126 | 272 | 235 |
| Capex / Sales | 10.63% | 3.73% | 22.96% | 7.09% | 13.32% | 11.48% |
| Announcement Date | 4/18/19 | 4/28/20 | 4/15/21 | 4/28/22 | 4/27/23 | 4/18/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -1.24% | 1.63B | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.18B | |
| +3.98% | 3.16B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -8.96% | 1.6B | |
| +39.87% | 1.44B |
- Stock Market
- Equities
- 002287 Stock
- Financials Tibet Cheezheng Tibetan Medicine Co., Ltd.
